4SC AG (VSC) - Financial and Strategic SWOT Analysis Review
4SC AG is a Germany based research oriented company which concentrates mainly on the discovery of the drugs as well as its development. The main focus of the research is centered on cancer and autoimmune indications. 4SC develops drug candidates until proof-of-concept in order to generate value creating partnerships with the pharmaceutical industry in return for advance and milestone payments as well as royalties. It collaborates with AiCuris in the field of antiviral and antibacterial drug discovery, with ProQinase to identify a new generation of protein kinase inhibitors in order to develop anticancer drugs, with and ViroLogik in the field of developing, manufacturing and market the compound for viral diseases. The company is having 91 employees till 2009 and it is headquartered in Martinsried, Germany.
4SC AG Key Recent Developments…
May 10, 2011: 4SC Reports Net Loss Of €4.7m For Q1 2011 May 26, 2010: Phase Ii Hodgkin Lymphoma Study With Hdac Inhibitor Resminostat Advances Into The Second Recruitment Stage Apr 16, 2010: 4SC And Nexigen Receive EUR 1.4 Million Funding From German Federal Ministry Of Education And Research Feb 11, 2010: 4sc Announces Treatment Of First Patient In A Phase I Study Of 4sc-205 Jan 21, 2010: 4SC Initiates Dosing In First-in-Man Phase I 4SC-203 Study
This comprehensive SWOT profile of 4SC AG provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – Analyst’s summarization of the company’s business strategy. - SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats. - Company history – Progression of key events associated with the company. - Major products and services – A list of major products, services and brands of the company. - Key competitors – A list of key competitors to the company. - Key employees – A list of the key executives of the company. - Executive biographies – A brief summary of the executives’ employment history. - Key operational heads – A list of personnel heading key departments/functions. - Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company. - Key manufacturing facilities – A list of key manufacturing facilities of the company. - Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. - The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably. - Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance. - Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research. - Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 4 Section 1 - About the Company 5 4SC AG - Key Facts 5 4SC AG - Key Employees 6 4SC AG - Key Employee Biographies 7 4SC AG - Major Products and Services 8 4SC AG - Pharmaceutical Pipeline Products Data 9 4SC AG, Pipeline Products by Therapy Area 9 4SC AG, Pipeline Products by Development Phase 10 4SC AG - History 12 4SC AG - Company Statement 13 4SC AG - Locations And Subsidiaries 15 Head Office 15 Section 2 – Company Analysis 16 4SC AG - Business Description 16 4SC AG - SWOT Analysis 18 SWOT Analysis - Overview 18 4SC AG - Strengths 18 Strength - Intellectual Property 18 Strength - 4SCan Technology 18 4SC AG - Weaknesses 18 Weakness - Declining Market Share in Sector 18 Weakness - Lack of manufacturing facilities 18 4SC AG - Opportunities 19 Opportunity - Market Potential: Cancer 19 Opportunity - Focused R&D activities 19 Opportunity - Treatment for Rheumatoid Arthritis 19 4SC AG - Threats 19 Threat - Industry Consolidation 19 Threat - Uncertain R&D Outcomes 19 Threat - Growing Parallel Trade 20 4SC AG - Key Competitors 21 Section 3 – Company Financial Ratios 22 Financial Ratios - Capital Market Ratios 22 Financial Ratios - Annual Ratios 22 Performance Chart 24 Financial Performance 24 Financial Ratios - Interim Ratios 25 Financial Ratios - Ratio Charts 26 Section 4 – Company’s Lifesciences Financial Deals and Alliances 27 4SC AG, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011 27 4SC AG, Pharmaceuticals & Healthcare, Deals By Type, 2005 to YTD 2011 28 4SC AG, Recent Deals Summary 29 Section 5 – Company’s Recent Developments 30 May 10, 2011: 4SC Reports Net Loss Of €4.7m For Q1 2011 30 May 26, 2010: Phase Ii Hodgkin Lymphoma Study With Hdac Inhibitor Resminostat Advances Into The Second Recruitment Stage 31 Apr 16, 2010: 4SC And Nexigen Receive EUR 1.4 Million Funding From German Federal Ministry Of Education And Research 31 Feb 11, 2010: 4sc Announces Treatment Of First Patient In A Phase I Study Of 4sc-205 31 Jan 21, 2010: 4SC Initiates Dosing In First-in-Man Phase I 4SC-203 Study 32 Jan 12, 2010: 4sc Announces First Patient Treated In A Phase Ii Hodgkin’s Lymphoma Study With Hdac Inhibitor Resminostat (4sc-201) 33 Jan 11, 2010: 4SC Initiates Treatment In Phase II Study Evaluating Resminostat 33 Section 6 – Appendix 35 Methodology 35 Ratio Definitions 35 About GlobalData 39 Contact Us 39 Disclaimer 39 List of Tables 4SC AG, Key Facts 5 4SC AG, Key Employees 6 4SC AG, Key Employee Biographies 7 4SC AG, Major Products and Services 8 4SC AG, Number of Pipeline Products by Therapy Area 9 4SC AG, Number of Pipeline Products by Development Stage 10 4SC AG, Pipeline Products By Therapy Area and Development Phase 11 4SC AG, History 12 4SC AG, Key Competitors 21 4SC AG, Ratios based on current share price 22 4SC AG, Annual Ratios 22 4SC AG, Interim Ratios 25 4SC AG, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011 27 4SC AG, Pharmaceuticals & Healthcare, Deals By Type, 2005 to YTD 2011 28 4SC AG, Recent Deals Summary 29 Currency Codes 35 Capital Market Ratios 35 Equity Ratios 36 Profitability Ratios 36 Cost Ratios 37 Liquidity Ratios 37 Leverage Ratios 38 Efficiency Ratios 38 List of Figures 4SC AG, Pipeline Products by Therapy Area 9 4SC AG, Pipeline Products by Development Phase 10 4SC AG, Performance Chart (2006 - 2010) 24 4SC AG, Ratio Charts 26 4SC AG, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011 27 4SC AG, Pharmaceuticals & Healthcare, Deals by Type, 2005 to YTD 2011 28
3DM Inc. - Strategic SWOT Analysis ReviewSummary3DM Inc. (3DM) is a privately held specialty biomaterials and medical device company. It is a subsidiary of 3D-Matrix, Ltd, Japan. The company develops ...Read More
3M Health Care - Strategic SWOT Analysis ReviewSummary3M Health Care, a business segment of 3M Company, provides medical and oral care products, drug delivery and health information systems worldwide. ...Read More
Summary3SBio Inc. (3S Bio) is a biotechnology company with focus on the research and development, manufacturing and marketing of biopharmaceutical products in China. It develops recombinant, or geneti ...Read More
3Shape A/S. Market Share AnalysisSummaryGlobalData’s new report, “3Shape A/S. Market Share Analysis” provides in-depth information on 3Shape A/S.’s market position in the CAD/CAM dental system ...Read More
3WIN nv - Product Pipeline AnalysisSummary3WIN nv (3WIN) is engaged in the development and marketing of active implantable medical devices. The company is developing a deep brain stimulator (DBS), whi ...Read More
4SC AG (VSC) - Financial and Strategic SWOT Analysis ReviewSummary4SC AG is a Germany based research oriented company which concentrates mainly on the discovery of the drugs as well as its development ...Read More
SummaryA&G Pharmaceutical, Inc. (A&G) is a pharmaceutical company, based in the US. The company develops therapeutic and diagnostic products for the in-vitro diagnostic markets. Its products include b ...Read More
A-dec Inc. GmbH Market Share AnalysisSummaryGlobalData’s new report, “A-dec Inc. GmbH Market Share Analysis” provides in-depth information on A-dec Inc..’s market position in the dental device ...Read More
For support please contact: US Toll Free
+1 888-789-6604 Asia Pacific
To receive alerts about an update, future offers and discounts on this report, signup here. Email ID